Background Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. Psoriasis impacts on
Introduction
Moderate to severe plaque psoriasis has a recognized impact on the physical and emotional well-being of patients. 1 Some existing treatments for plaque psoriasis can achieve a ≥ 75% reduction in Psoriasis Area Severity Index (PASI75 response) in over half of patients. [2] [3] [4] However, such clinical efficacy endpoints do not reflect the complete patient experience. For example, itch is a major symptom of psoriasis and is known to negatively impact the health-related quality of life (HRQoL). 5, 6 In addition,
In order to improve the patient experience, a more holistic approach to outcomes assessment is required, which encompasses patient-reported outcomes (PROs) as well as physician efficacy assessment. Thus, clinical evaluation of treatment efficacy in psoriasis should include measures that evaluate the totality of symptoms and patient perceptions. Etanercept, a biologic agent, has shown improvements in patient-reported measures of HRQoL in psoriasis. 10 However, head-to-head studies that compare clinical efficacy and PROs with an oral small-molecule agent vs. a biologic agent in the psoriasis setting are limited. 11, 12 Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. In the Phase 3 Oral-treatment Psoriasis Trial (OPT) Compare Study, tofacitinib 10 mg twice daily (BID) demonstrated non-inferiority to etanercept 50 mg twice weekly (BIW) and superiority to placebo, with regard to PASI75 and Physician Global Assessment (PGA), at Week 12. Non-inferiority to etanercept was not demonstrated for tofacitinib 5 mg BID. Both tofacitinib (5 and 10 mg BID) and etanercept were well tolerated. 13 Specific HRQoL data were collected during the OPT Compare Study 13 and are being presented here, separately from the primary efficacy results, to allow for a more detailed assessment and discussion. The objective of the present analysis was to examine the impact of tofacitinib (an orally administered small molecule) compared with etanercept (an established, frequently used biologic) or placebo on PROs and HRQoL in patients with moderate to severe psoriasis, using data from the Phase 3 OPT Compare Trial.
Materials and methods

Study design, patients and treatment
The study design and methods have been described previously (clinicaltrials.gov; NCT01241591). 13 Briefly, the OPT Compare Study was a Phase 3, randomized, double-blind, double-dummy, placebo-controlled, active comparator study in adult patients with moderate to severe chronic plaque psoriasis (duration ≥ 12 months) and with a PASI score of 12 or higher, a PGA score of 'moderate' or 'severe' (on a five-point severity scale of: 0 'clear'; 1 'almost clear'; 2 'mild'; 3 'moderate'; 4 'severe') and at least 10% affected body surface area. Patients had failed to respond, had contraindication or were intolerant to at least one conventional systemic psoriasis therapy. 18 The SF-36 version 2 acute form, with a 1-week recall period, was utilized and administered at Day 1 (baseline) and Week 12 (or the end of treatment).
Statistical analyses
The full analysis set (FAS) was used for all analyses of PROs and included all patients who were randomized in the trial and received at least 1 dose of randomized investigational drug (tofacitinib, etanercept or placebo). For continuous endpoints, the change from baseline was analyzed using a mixed-effect, repeated-measures model. The least-squares (LS) mean differences between tofacitinib and etanercept, or placebo, and the associated 95% confidence intervals were derived from this model. Binary endpoints were analyzed using the normal approximation for the difference in binomial proportions between tofacitinib and etanercept, or placebo, with missing values handled by non-responder imputation. No adjustments were made for multiple testing, and nominal P values were displayed.
Results
Baseline characteristics and the results of the primary analysis, including PASI75 response, PGA response and clinically meaningful reduction in DLQI, have been reported previously. 13 PRO measurements at baseline indicated a substantial burden of psoriasis, with 67.1% of patients (733/1093) reporting a PtGA score of 'severe' and 29.6% (324/1093) reporting a score of 'moderate' (Table 1 ). In comparison, physicians generally rated patients' disease less severely and assigned a PGA score of 'severe' to 16.9% of patients and a score of 'moderate' to 81.6% of patients. Similar to the PtGA data, baseline DLQI scores reflected an impact of psoriasis on HRQoL: 14.9% (163/1092) of patients had a DLQI score of 21-30 (extremely large effect), 45.7% (499/1092) had a DLQI score of 11-20 (a very large effect), and a further 22.8% (249/1092) had a DLQI score of 6-10 (a moderate effect). 19 The mean 
Itch
A rapid and substantial decrease from baseline in itch (measured by ISI) was observed in patients receiving tofacitinib 10 and 5 mg BID (Fig. 3) . Within 1 day of starting treatment, both tofacitinib doses demonstrated statistically significant reductions from baseline in LS mean (SE) ISI score: À1.0 (0.1) for both tofacitinib 5 and 10 mg BID (both P < 0.05 vs. placebo). Significant improvements in itch with active treatment (vs. placebo) were maintained through Weeks 2, 4, 8 and 12 (P < 0.001 for etanercept at Week 2 and P < 0.0001 for all other comparisons; Fig. 3 ). Reductions in itch with tofacitinib 10 mg BID were significantly larger vs. etanercept (P < 0.05 for all time points; Fig. 3 ). Of those patients with an ISI score > 1 at baseline, the proportion who achieved 'little or no itch' (ISI ≤ 1) increased steadily in all active treatment groups over time, with the most rapid and substantial improvements observed with tofacitinib 10 mg BID, followed by tofacitinib 5 mg BID and etanercept 50 mg BIW (Fig. 4) . Furthermore, a greater proportion of patients achieved 'little or no itch' at Week 2 onwards with tofacitinib 10 mg BID than with etanercept 50 mg BIW (P < 0.05 at all subsequent time points). At Week 12, the highest proportion of patients with 'little or no itch' was observed in the tofacitinib 10 PROs with tofacitinib, etanercept and placebo
PtGA
The PtGA response rate in the tofacitinib 10 mg BID group was significantly greater vs. placebo at Week 2 (P < 0.05), indicating a rapid onset of effect (Fig. 5) . From Week 4 onwards, the response rate for all active treatment groups was significantly greater than with placebo (P < 0.0001 for all comparisons). In addition, there was a higher proportion of responders in the tofacitinib 10 mg BID group vs. etanercept 50 mg BIW group at Week 4 and Week 8 (P < 0.05 for both comparisons). By Week 12, the response rates were similar in the tofacitinib 10 mg BID and etanercept groups (51.8% and 49.0%, respectively) compared with 30.4% for tofacitinib 5 mg BID and 0.9% for placebo.
SF-36 PCS and MCS scores
Improvements in PCS and MCS scores were observed in all groups at Week 12 ( Table 2 ). In active treatment groups, mean PCS exceeded the mean age-and gender-matched normative value, whereas in the placebo group, they remained below this value. Similarly, MCS scores in active treatment groups approached normative values, while corresponding values in the placebo group remained low (data not shown). A highly significant improvement from baseline in health status was observed for all eight domains and scores of the SF-36 in all active treatment groups at Week 12, compared with the placebo group (P < 0.001 for 'general health' and 'health transition score'; P < 0.0001 for all other domains and scores; Table 2 ).
Discussion
From a patient perspective, the importance of PROs in psoriasis management should not be understated. Improvements in PROs are not only associated with better HRQoL for the patient 20 but also have a positive secondary impact on the lives of patients' relatives and partners. 21 Nevertheless, studies on patient perspectives suggest a disconnect with physicians regarding the with a DLQI score of ≤ 1, indicating 'no effect of psoriasis on quality of life' (FAS, NRI). *P < 0.05, ***P < 0.0001 vs. placebo. BID, twice daily; BIW, twice weekly; FAS, full analysis set; DLQI, Dermatology Life Quality Index; NRI, non-responder imputation; SE, standard error. extent of disease that patients experience. 22, 23 Here, we found that patients rate their disease more severely than physicians do, highlighting the need for greater physician-patient communication in order to fully understand the patient experience. The Phase 3 OPT Compare Study in patients with moderate to severe psoriasis was the first direct head-to-head comparison of the oral small-molecule tofacitinib with the biologic agent etanercept (the standard-of-care treatment in this setting). In this analysis, significant improvements in patient-reported measures of disease severity and improvements across multiple domains of HRQoL were observed with tofacitinib by Week 12 and often considerably earlier. Compared with etanercept, the magnitude of improvements in PROs with tofacitinib was comparable in patients dosed with 5 mg BID and greater in patients dosed with 10 mg BID -findings that complement the observed primary efficacy outcomes. 13 It should be noted that the dose of LS mean change from baseline (SE) Day * * * * *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** The last patient diary entry was scheduled for the evening before the Week 2 visit. However, not all patients completed the diary for the entirety of the intended period. Also, the window for the Week 2 visit was Day 15 AE 3 days; hence, the Week 2 visit did not necessarily take place on Day 15 for all participants. The Week 2 assessment was made for all patients at the clinic, and these differences account for the apparent difference in ISI values between Day 15 and Week 2. etanercept evaluated in the trial (50 mg BIW) is the highest dose approved by the US Food and Drug Administration and European Medicines Agency for the treatment of psoriasis 24 and may be given for up to 12 weeks. 25 The reliability and validity of the DLQI in a psoriasis population has been well documented. 26 In addition, the minimally important difference (MID) in DLQI has been estimated as a ≥ 5-point change from baseline, 27 which was achieved by 66.3% (tofacitinib 5 mg BID), 78.2% (tofacitinib 10 mg BID) and 74.7% (etanercept) of patients in this trial. 13 A recent reassessment of the MID in DLQI led to the recommendation that the MID should be lowered to 4, 28 which would mean that an even greater proportion of patients in this trial achieved a clinically significant improvement in DLQI. In addition to PASI75 responders, we also examined a composite endpoint defined by European consensus guidelines for the treatment goals of moderate to severe psoriasis. 15 These guidelines recommend that in patients who achieve an improvement in PASI score ≥ 50% but < 75%, treatment should be continued if DLQI is ≤ 5 or modified if the DLQI score is > 5 at the end of induction therapy or during maintenance therapy. In our study, more than 70% of patients receiving tofacitinib 10 mg BID or etanercept 50 mg BIW, and more than 50% of patients receiving tofacitinib 5 mg BID, achieved this composite endpoint of PASI75 or PASI50-75 with DLQI ≤ 5.
Itch is considered by patients to be the most bothersome symptom of psoriasis 29 and is more likely to cause absence from work and reduced work productivity than psoriasisrelated pain or scaling. 30 In the present study, a rapid onset of treatment effect on itch was observed as early as within 1 day of starting treatment; improvements in itch were seen earlier with tofacitinib 10 mg BID than with etanercept. Given the considerable burden that itch represents for patients with psoriasis, and that itch relief can often be slow even with treatment, this finding indicates that tofacitinib may be associated with more effective and quicker relief from itch compared with etanercept, which would be of great importance to patients. Potential limitations of this study include its relatively short duration of 12 weeks. Long-term studies of tofacitinib in moderate to severe psoriasis are ongoing; 1-year data show sustained improvements in DLQI and itch (measured by ISI) with tofacitinib. 31 In conclusion, this study demonstrates that tofacitinib is effective across a range of signs and symptoms of moderate to severe plaque psoriasis, including PROs and HRQoL. In general, improvements in PROs and HRQoL observed with tofacitinib 10 mg BID were comparable with etanercept. However, improvements in itch were greater and more rapid with tofacitinib 10 mg BID vs. etanercept, suggesting that tofacitinib may represent a potential future treatment option for patients with moderate to severe plaque psoriasis.
